Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in
BRCA1
BRCA2
breast cancer
estrogen receptor
germline mutations
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 May 2019
28 May 2019
Historique:
received:
28
03
2019
revised:
16
05
2019
accepted:
24
05
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
31
5
2019
Statut:
epublish
Résumé
Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers;
Identifiants
pubmed: 31141992
pii: cancers11060738
doi: 10.3390/cancers11060738
pmc: PMC6627684
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NV15-28830A
Organisme : Univerzita Karlova v Praze
ID : PROGRES Q28/LF1
Organisme : Univerzita Karlova v Praze
ID : SVV2018/260367
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest.
Références
Med Princ Pract. 2003 Jan-Mar;12(1):23-9
pubmed: 12566964
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
Breast Cancer Res. 2005;7(5):R728-36
pubmed: 16168118
Am J Surg Pathol. 2006 Sep;30(9):1097-104
pubmed: 16931954
N Engl J Med. 2007 Jul 12;357(2):115-23
pubmed: 17625123
JAMA. 2008 Jan 9;299(2):194-201
pubmed: 18182601
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Breast Cancer Res Treat. 2010 Nov;124(2):337-47
pubmed: 20135348
Breast Cancer Res. 2010;12(1):R12
pubmed: 20149218
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
J Clin Oncol. 2010 Sep 20;28(27):4214-20
pubmed: 20733129
Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
pubmed: 20877296
J Clin Oncol. 2012 Jan 1;30(1):19-26
pubmed: 22147742
Cancer. 2012 Nov 15;118(22):5463-72
pubmed: 22544643
J Clin Oncol. 2013 Sep 10;31(26):3191-6
pubmed: 23940229
Clin Cancer Res. 2015 Jan 1;21(1):211-20
pubmed: 25348513
PLoS One. 2015 Mar 27;10(3):e0120189
pubmed: 25816289
Breast Cancer Res. 2014 Dec 23;16(6):3419
pubmed: 25857409
Clin Genet. 2016 Oct;90(4):324-33
pubmed: 26822949
Cancer. 2016 Apr 15;122(8):1178-84
pubmed: 26859126
Breast. 2016 Aug;28:136-44
pubmed: 27318168
Br J Cancer. 2016 Sep 27;115(7):776-83
pubmed: 27537391
Clin Cancer Res. 2017 Mar 1;23(5):1236-1241
pubmed: 27620280
Medicine (Baltimore). 2016 Oct;95(40):e4975
pubmed: 27749552
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376189
Breast Cancer Res Treat. 2017 Sep;165(2):391-402
pubmed: 28601929
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Clin Cancer Res. 2017 Oct 15;23(20):6113-6119
pubmed: 28724667
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092
PLoS One. 2018 Apr 12;13(4):e0195761
pubmed: 29649263
Breast Cancer Res. 2018 Jul 11;20(1):74
pubmed: 29996906
Int J Biol Sci. 2018 Oct 3;14(12):1755-1768
pubmed: 30416390
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Br J Cancer. 2019 Feb;120(4):398-403
pubmed: 30723304
Am J Hum Genet. 1997 May;60(5):1013-20
pubmed: 9150148